490P - NY-ESO expression in osteosarcoma (490P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Bone Sarcomas
Sarcoma
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Piotr Rutkowski
Citation Annals of Oncology (2017) 28 (suppl_10): x149-x152. 10.1093/annonc/mdx675
Authors I. Lugowska1, T. Klepacka2, A. Szumera-Cieckiewicz3, E. Michalak2, M. Lenarcik3, A. Pienkowski4, P. Teterycz4, K. Szamotulska5, P. Rutkowski4
  • 1Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw/PL
  • 2Pathology, Institute of Mother and Child, Warsaw/PL
  • 3Pathology, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 4Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 5Biostatistics, Institute of Mother and Child, Warsaw/PL

Abstract

Background

New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a cancer-testis antigen expressed in normal tissue (male germ cells), as well as in breast, or lung cancers, hepatocellular carcinomas, melanomas, or soft tissues sarcomas. In early phase clinical trials, NY-ESO-1 is being studied as possible target for a cancer vaccine, immunotherapy, or in experimental engineered T-cell treatment. The aim of this study was to determine the frequency of expression of NY-ESO-1 protein in osteosarcoma patient population, and to correlate NY-ESO-1 expression with clinical outcomes.

Methods

We analysed 160 biopsy samples of osteosarcoma patients (aged 4-65 years; median 15 years; 59 women and 101 men). Twenty eight patients had metastatic disease at presentation, 11 – axial localisation of primary tumour, and all patients received multimodality treatment. Follow-up period was at least 5 years. The expression of NY-ESO was assessed with immunohistochemical staining in pretreatment samples. The cut-off points of NY-ESO-1 expression were 0% and 50%. Univariate analyses were conducted to assess the relationship between NY-ESO-1 expression and clinical outcomes.

Results

NY-ESO-1 expression in osteosarcoma was present in 22.5% cases. The only one significant relationships was found between NY-ESO-1 and clinical stage (localised/dissemination); p = 0.047. There was no other statistically significant relations between NY-ESO-1 and clinical outcomes such as overall survival, progression/disease free survival, patient age, gender, osteosarcoma subtype or its aggressiveness.

Conclusions

Immunotherapeutic strategies to target NY-ESO-1-expressing lesions in osteosarcoma may be addressed to limited proportion patients. There is no data confirming the utility of assessment of NY-ESO-1 as a prognostic factor in osteosarcoma.

Clinical trial identification

Legal entity responsible for the study

Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

Funding

None

Disclosure

P. Rutkowski: Received honoraria for lectures from Novartis, Roche, Pfizer, BMS, MSD and served as a member of Advisory Board for Novartis, Merck, Amgen, Blueprint, Roche, BMs and MSD.

All other authors have declared no conflicts of interest.